
MRNA vs EXEL
$MRNA vs $EXEL head to head: price, market cap, valuation, dividend, free float, relative volume and how actively each trades. The bigger value in the size rows is bolded. Tap either ticker for its live chart, full ownership breakdown and real-time alerts.
MRNA vs EXEL: trend, levels and the market
One year to 2026-11-19, against the S&P 500 (+9.7%). Split-adjusted daily closes.
- ·EXEL has the cleaner trend, above both its 50- and 200-day averages, where MRNA is above one and below the other.
- ·Both beat the market over the past year: MRNA +791% and EXEL +57.6%, against the S&P 500 at +9.7%.
- ·The last month has flipped the order: EXEL leads over the month (+1.9% against -18.9%) even though MRNA leads over the year.
- ·MRNA sits closer to its support, 9.6% above it at $179.56, while EXEL is 13.1% above its own at $56.90.
Support and resistance are daily prices the stock has turned at three or more times, within 35% of the price. The loading zone is the nearby price where the heaviest volume traded. These describe where a stock has been, not where it will go. Not investment advice.
MRNA vs EXEL: the quick read
- ·MRNA is the larger company by market cap ($80.65B vs $16.06B).
- ·MRNA has been more active on our scanner (355 vs 115 alerts in 30 days).
- ·EXEL has the smaller float (226.8M vs 360.3M), which tends to mean sharper, more volatile moves.
- ·Both are biological products, (no diagnostic substances) names, so this is a like-for-like comparison and sector news tends to move them together.
- ·MRNA draws far more of our scanner's attention, 355 unusual-volume alerts in 30 days against 115, so it is the more actively traded of the two by some distance.
Objective differences only. Not investment advice.
Watching MRNA or EXEL? Get each morning’s movers by email
Free daily email of the top plays and unusual-volume alerts our scanner flags. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Frequently asked questions
Everything you need to know comparing MRNA and EXEL on TheDesperateTrader.
- Is MRNA or EXEL the better stock?
- "Better" depends on your goal, and these two are not alike. MRNA is the larger company by market cap ($80.65B vs $16.06B). MRNA has been more active on our scanner (355 vs 115 alerts in 30 days). EXEL has the smaller float (226.8M vs 360.3M), which tends to mean sharper, more volatile moves. Those are the measured differences, not a recommendation, and nothing here is investment advice.
- What is the difference between MRNA and EXEL?
- The differences that matter: MRNA is roughly 5x the size of the other by market cap ($80.65B vs $16.06B); they trade at very different share prices ($198.57 vs $65.50); MRNA sits at 68% of its 52-week range against 76% for EXEL; our scanner flagged MRNA 355 times in the last 30 days against 115 for EXEL. Everything above is measured from the latest completed session and SEC filings.
- Which of MRNA and EXEL is more active right now?
- Right now MRNA is at about 0.5x its normal volume and EXEL is at about 1.0x, so EXEL is the one drawing unusual attention today. Relative volume (RVOL) compares a stock's volume to its own recent average, so it reads the same way for a megacap and a microcap and is the quickest way to tell which of two similar names is actually in play.
- Is MRNA or EXEL in the stronger trend?
- MRNA is below its 50-day average of $206.87 and above its 200-day average of $99.64; EXEL is above its 50-day average of $63.03 and above its 200-day average of $52.75. MRNA leads 3 of the 5 measures on this page (1 year, vs S&P 500, 3 months, 1 month, trend). A trend is where a stock has been, not a forecast, and nothing here is investment advice.
- Is this comparison data live?
- Prices and % changes are anchored to the latest completed session and split-adjusted, so a reverse split never shows as a fake move. Float is estimated from SEC filings and refreshed as new filings publish.
Trading MRNA or EXEL? Get real-time unusual-volume alerts the moment either one moves, free.
No card · 5 premium daysMore MRNA and EXEL comparisons
Same sector, similar size. These are the peers each one is usually weighed against.
Explore the market
Free, live market tools. No account required to look.